Mark A. Goldsmith, M.D., Ph.D.
Founding President, CEO and Director, Revolution Medicines
Previously, Partner with Third Rock Ventures in its West Coast office. Prior to this, Dr. Goldsmith served as President and Chief Executive Officer of Constellation from 2009 to 2012. He previously held senior executive positions in the biotechnology industry, including Senior Executive-in-Residence at Prospect Venture Partners, CEO of Cogentus Pharmaceuticals and Senior Vice President of Genencor International. Before entering the private sector, Dr. Goldsmith led a medical research laboratory at the Gladstone Institute of Virology and Immunology, practiced medicine on the faculty of the School of Medicine of the University of California, San Francisco and the San Francisco General Hospital, and was a consultant to leading pharmaceutical and biotechnology companies.
Anthony Evnin, Ph.D.
Dr. Evnin is a Partner of Venrock, a venture capital firm, where he has been a Partner since 1975. He currently serves on the boards of AVEO Pharmaceuticals, Inc., Infinity Pharmaceuticals, Inc., and Pharmos Corporation as well as a number of private companies. Dr. Evnin is a Trustee of The Rockefeller University, a Trustee of The Jackson Laboratory, a Trustee Emeritus of Princeton University, and a Member of the Boards of Overseers and Managers of Memorial Sloan-Kettering Cancer Center. Dr. Evnin holds a Ph.D. in Chemistry from the Massachusetts Institute of Technology and an A.B. from Princeton University.
Managing Partner and Founder, The Column Group
Peter has 30 years of experience in corporate finance, investment banking, and venture capital. He was the founder and a partner of Three Crowns Capital, a leading backer of a new generation of US biotechnology companies. He helped found companies such as Rosetta, PTC, Tercica, and Somalogic. Over the past 12 years he has helped finance and develop biotech companies, including Tularik, Sunesis, Chemocentryx, Infinity, AVEO, Rinat, and FivePrime. He is currently a Board Director of NGM Biopharmaceuticals, Immune Design, and Gritstone and has served on the Boards of several other biotechnology companies, including Seragon Pharmaceuticals (Chairman), Aragon Pharmaceuticals (Chairman), Rosetta, Somalogic, and ChemoCentryx. Before founding Three Crowns Capital, he was the Associate Managing Director of European Investment Banking Origination at Nomura Securities in London. He is currently a trustee for the Institute for Advanced Study in Princeton, New Jersey.
Robert Tepper, M.D.
Partner, Third Rock Ventures
Dr. Tepper co-founded Third Rock Ventures in 2007 and serves as a Partner. Dr. Tepper works actively with portfolio companies to shape their scientific strategy. In this capacity Dr. Tepper worked as CSO of Constellation from April 2008 to October 2009. Prior to joining Third Rock Ventures, Dr. Tepper was President of R&D at Millennium Pharmaceuticals and co-founder of Cell Genesys/Abgenix. Dr. Tepper serves as an adjunct faculty member at Harvard Medical School and Massachusetts General Hospital and is an advisory board member of several leading health care institutions including the Partners HealthCare Center for Personalized Genetic Medicine, Tufts Medical School, and a member of the Research Advisory Council of Massachusetts General Hospital.